What is Mesosil?
Mesosil specializes in developing next-generation anti-infective solutions leveraging an innovative silica-based platform. This technology facilitates high-capacity delivery and sustained release of bioactive agents, with initial applications in reducing recurrent tooth decay in dental materials. The company's solutions are designed for seamless integration into existing manufacturing processes, offering long-term antimicrobial protection. Mesosil is also exploring its platform's potential in orthopedics and implantable devices, aiming to address critical challenges in infection prevention and biomaterial longevity.
How much funding has Mesosil raised?
Mesosil has raised a total of $1.6M across 1 funding round:
Angel/Seed
$1.6M
Angel/Seed (2024): $1.6M with participation from GreenSky Capital, GreyHill Group, NorthSpring Capital Partners, ArchAngel Network of Funds, and Centre for Aging and Brain Health Innovation
Key Investors in Mesosil
GreenSky Capital
GreenSky Capital is an investment firm that focuses on early-stage Canadian B2B start-ups led by exceptional entrepreneurs. Since its inception in 2015, the company has been dedicated to deploying capital to support promising ventures.
GreyHill Group
GreyHill Group specializes in commercial real estate investing, focusing on creating unique investment opportunities by enhancing asset value through improvements. The company employs a disciplined and transparent approach to drive value upwards in their portfolio.
NorthSpring Capital Partners
NorthSpring Capital Partners invests in passionate entrepreneurs and companies developing unique intellectual property, products, and services targeting large addressable markets. They provide financial resources and expertise to accelerate the growth of innovative companies located in the Toronto-Waterloo technology corridor.
What's next for Mesosil?
The recent major strategic investment signifies a pivotal moment for Mesosil, likely enabling the company to accelerate product development, scale manufacturing capabilities, and expand its market reach. This capital will be instrumental in further validating its silica-based platform for broader applications beyond dental materials, potentially into the orthopedic and implantable device sectors. The enterprise-level backing suggests confidence in Mesosil's technology and its potential to disrupt infection prevention strategies across multiple industries.
See full Mesosil company page
